Cargando…

A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets

OBJECTIVE: The presence of elevated dopamine (DA) and its major metabolites in the cytosol of neurons has been associated with their vulnerability in Parkinson's disease (PD). Over 99% of the cell's amines are confined to secretory vesicles (SVs), making these structures fundamental in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Montenegro, Pablo, Pueyo, Mercedes, Lorenzo, Jesús Norelis, Villar‐Martinez, María Dolores, Alayón, Antonio, Carrillo, Francisco, Borges, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315021/
https://www.ncbi.nlm.nih.gov/pubmed/35226382
http://dx.doi.org/10.1002/ana.26335
_version_ 1784754459713208320
author Montenegro, Pablo
Pueyo, Mercedes
Lorenzo, Jesús Norelis
Villar‐Martinez, María Dolores
Alayón, Antonio
Carrillo, Francisco
Borges, Ricardo
author_facet Montenegro, Pablo
Pueyo, Mercedes
Lorenzo, Jesús Norelis
Villar‐Martinez, María Dolores
Alayón, Antonio
Carrillo, Francisco
Borges, Ricardo
author_sort Montenegro, Pablo
collection PubMed
description OBJECTIVE: The presence of elevated dopamine (DA) and its major metabolites in the cytosol of neurons has been associated with their vulnerability in Parkinson's disease (PD). Over 99% of the cell's amines are confined to secretory vesicles (SVs), making these structures fundamental in the regulation of cytosolic DA levels. SVs of platelets use similar, if not the same mechanisms to accumulate serotonin in SVs as dopaminergic neurons do to store DA. Hence, any functional defects in platelets probably mirrors events in DA neurons. METHODS: We have isolated fresh platelets from the blood of 75 PD patients, 116 matched controls and 24 patients with Parkinsonism, assaying serotonin handling (basal content, accumulation, secretion and spontaneous leakage). RESULTS: We found a dramatic decrease in the serotonin content and uptake by SVs, as well as decreased thrombin‐induced release by platelets from PD patients but not in those from most Parkinsonism cases. Platelets from PD patients also failed to retain serotonin in SVs. INTERPRETATION: These findings indicate a functional impairment in the handling of amines by SVs in PD patients. This defect may serve as a biomarker of PD, and the approach described here may be potentially used for the subclinical detection of PD and to establish a platform to assay disease modifying drugs. ANN NEUROL 2022
format Online
Article
Text
id pubmed-9315021
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-93150212022-07-30 A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets Montenegro, Pablo Pueyo, Mercedes Lorenzo, Jesús Norelis Villar‐Martinez, María Dolores Alayón, Antonio Carrillo, Francisco Borges, Ricardo Ann Neurol Research Articles OBJECTIVE: The presence of elevated dopamine (DA) and its major metabolites in the cytosol of neurons has been associated with their vulnerability in Parkinson's disease (PD). Over 99% of the cell's amines are confined to secretory vesicles (SVs), making these structures fundamental in the regulation of cytosolic DA levels. SVs of platelets use similar, if not the same mechanisms to accumulate serotonin in SVs as dopaminergic neurons do to store DA. Hence, any functional defects in platelets probably mirrors events in DA neurons. METHODS: We have isolated fresh platelets from the blood of 75 PD patients, 116 matched controls and 24 patients with Parkinsonism, assaying serotonin handling (basal content, accumulation, secretion and spontaneous leakage). RESULTS: We found a dramatic decrease in the serotonin content and uptake by SVs, as well as decreased thrombin‐induced release by platelets from PD patients but not in those from most Parkinsonism cases. Platelets from PD patients also failed to retain serotonin in SVs. INTERPRETATION: These findings indicate a functional impairment in the handling of amines by SVs in PD patients. This defect may serve as a biomarker of PD, and the approach described here may be potentially used for the subclinical detection of PD and to establish a platform to assay disease modifying drugs. ANN NEUROL 2022 John Wiley & Sons, Inc. 2022-03-15 2022-05 /pmc/articles/PMC9315021/ /pubmed/35226382 http://dx.doi.org/10.1002/ana.26335 Text en © 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Montenegro, Pablo
Pueyo, Mercedes
Lorenzo, Jesús Norelis
Villar‐Martinez, María Dolores
Alayón, Antonio
Carrillo, Francisco
Borges, Ricardo
A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets
title A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets
title_full A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets
title_fullStr A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets
title_full_unstemmed A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets
title_short A Secretory Vesicle Failure in Parkinson's Disease Occurs in Human Platelets
title_sort secretory vesicle failure in parkinson's disease occurs in human platelets
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315021/
https://www.ncbi.nlm.nih.gov/pubmed/35226382
http://dx.doi.org/10.1002/ana.26335
work_keys_str_mv AT montenegropablo asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT pueyomercedes asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT lorenzojesusnorelis asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT villarmartinezmariadolores asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT alayonantonio asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT carrillofrancisco asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT borgesricardo asecretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT montenegropablo secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT pueyomercedes secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT lorenzojesusnorelis secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT villarmartinezmariadolores secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT alayonantonio secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT carrillofrancisco secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets
AT borgesricardo secretoryvesiclefailureinparkinsonsdiseaseoccursinhumanplatelets